** Drug developer BridgeBio's BBIO.O shares rise 25% to $29.29 premarket
** The FDA on Friday approved BBIO's heart disease drug Attruby
** Co's oral drug was approved to treat a rare heart condition known as transthyretin amyloid cardiomyopathy that makes it hard for the heart to pump blood
** BBIO's drug is expected to compete with Pfizer's PFE.N Vyndaqel and Vyndamax
** As of last close, BBIO down ~42% YTD
(Reporting by Bhanvi Satija in Bengaluru)
((Bhanvi.Satija@thomsonreuters.com; Outside U.S. +91 9873062788;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.